Disc Medicine Late-Stage Trial Win Clears Path to Resubmit Approval Application
Disc Medicine said its experimental pill for a rare disease helped patients spend more time in sunlight without pain. The company can resubmit its application; shares rose 35% in early trading.
Story updates
04:23:03 PM UTC
SquawkNews
By Lizzy Lawrence and Xavier MartinezShares of Disc Medicine rose around 37% on Monday after it announced that its experimental pill succeeded in easing symptoms in people with a rare disease that makes sunlight painful.Patients with the disease, called erythropoietic protoporphyria, accumulate a c…
Disc Medicine (NASDAQ: IRON) said on Monday that its experimental pill for a rare disease helped patients spend more time in sunlight without pain. Its shares surged 35% in early trading. The late-stage trial success sets the stage for Disc to resubmit its application for an…